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Abstract
Aims/hypothesis There is considerable variability in how diabetes progresses after diagnosis. Progression modelling has largely
focused on ‘time to failure’ methods, yet determining a ‘coefficient of failure’ has many advantages. We derived a rate of
glycaemic deterioration in type 2 diabetes, using a large real-world cohort, and aimed to investigate the clinical, biochemical,
pharmacological and immunological variables associated with fast and slow rates of glycaemic deterioration.
Methods An observational cohort study was performed using the electronic medical records from participants in the Genetics of
Diabetes Audit and Research in Tayside Study (GoDARTS). A model was derived based on an individual’s observed HbA1c
measures from the first eligible HbA1c after the diagnosis of diabetes through to the study end (defined as insulin initiation, death,
leaving the area or end of follow-up). Each HbA1c measure was time-dependently adjusted for the effects of non-insulin glucose-
lowering drugs, changes in BMI and corticosteroid use. GAD antibody (GADA) positivity was defined as GAD titres above the
97.5th centile of the population distribution.
Results The mean (95% CI) glycaemic deterioration for type 2 diabetes and GADA-positive individuals was 1.4 (1.3, 1.4) and
2.8 (2.4, 3.3) mmol/mol HbA1c per year, respectively. Ayounger age of diagnosis, lower HDL-cholesterol concentration, higher
BMI and earlier calendar year of diabetes diagnosis were independently associated with higher rates of glycaemic deterioration in
individuals with type 2 diabetes. The rate of deterioration in those diagnosed at over 70 years of age was very low, with 66%
having a rate of deterioration of less than 1.1 mmol/mol HbA1c per year, and only 1.5% progressing more rapidly than 4.4 mmol/
mol HbA1c per year.
Conclusions/interpretation We have developed a novel approach for modelling the progression of diabetes in observational data
across multiple drug combinations. This approach highlights how glycaemic deterioration in those diagnosed at over 70 years of
age is minimal, supporting a stratified approach to diabetes management.
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Introduction
Type 2 diabetes is a progressive disease, primarily
characterised by beta cell failure [1, 2]. This progression is
manifested clinically by a deterioration in HbA1c levels over
time, despite lifestyle and increased pharmacological inter-
ventions. However, the rate at which diabetes progresses is
highly variable between individuals. Some individuals have
a rapid deterioration and advance to insulin therapy quickly,
whereas others can be adequately treated with non-insulin
glucose-lowering medication for in excess of 20 years.
Gaining insight into why some individuals progress rapidly
while others do not will enable a more stratified approach to
the management of type 2 diabetes by identifying subgroups
who may require different management depending on their
likelihood of diabetes progression.
Previous studies have investigated factors associated with
the rate of diabetes progression. However, these studies have
only reported an outcome based on progression to glucose-
lowering medications (i.e. time to initiation of non-insulin
glucose-lowering medication, failure of monotherapy or time
to insulin therapy) [1, 3–9]. In these studies, younger age at
diagnosis and insufficient beta cell function were consistently
associated with faster progression of diabetes. The UK
Prospective Diabetes Study (UKPDS) reported that the pres-
ence of positive GAD antibody (GADA) concentrations pre-
dicted an increased likelihood of requirement for insulin [3].
Other less well established associations were female sex, low
BMI (defined as <30 kg/m2), weight gain, lower HDL-
cholesterol and higher serum creatinine. In addition, we have
previously reported that risk of progression, defined by a re-
quirement for insulin treatment, is associated with normal
weight or obesity (a U-shaped relationship), and higher
triacylglycerol and lower HDL-cholesterol levels [6].
The studies outlined rely on defining an endpoint, such as a
glycaemic threshold or starting a new drug. These ‘time to
failure’ approaches are problematic, particularly in the real
world, where decisions to start a drug may be subject to pre-
scriber or patient inertia, or where fluctuations in HbA1c, for
example due to lifestyle change resulting from life or health
status events, can trigger a failure event. A ‘coefficient of
failure’ measure has been proposed to avoid these difficul-
ties—in essence, deriving a rate of glycaemic deterioration
for each individual [10]. This approach was applied to the
UKPDS study, which reported a coefficient of failure of
3.7 mmol/mol (0.34%) per year with chlorpropamide treat-
ment [10], and to the A Diabetes Outcome Progression Trial
(ADOPT) study, which described a rate of glycaemic deterio-
ration of 1.5 mmol/mol (0.14%) HbA1c per year in the met-
formin monotherapy arm [11]. However, to our knowledge,
no studies have been reported describing the coefficient of
failure in settings outside these clinical trials of monotherapy.
Determining rates of deterioration in a population over time is
challenging as underlying disease severity reflects not only
•
•
•
•
•
•
•
•
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observed HbA1c, but also lifestyle and pharmacological
interventions.
The aim of this study was to derive a model for the rate of
deterioration of type 2 diabetes (coefficient of failure) in a
large population-based cohort and to investigate the clinical,
pharmacological, biochemical and immunological character-
istics associated with fast and slow rates of glycaemic
deterioration.
Methods
An observational cohort study was performed using compre-
hensive electronic medical records from individuals in the
Genetics of Diabetes Audit and Research in Tayside Study
(GoDARTS) database, which has previously been described
elsewhere [12, 13]. In short, this contains detailed information
on all encashed prescriptions from 1994 onwards in Tayside,
Scotland, as well as all biochemistry and BMI measures.
Therefore, for each individual we have a comprehensive lon-
gitudinal record of diabetes therapy and glycaemic control.
The GoDARTS study was approved by the Tayside
Committee on Medical Research Ethics, and informed con-
sent was obtained from all participants (REC reference 053/
04). The GoDARTS cohort and the research question outlined
here were studied as part of the Diabetes Research on Patient
Stratification (DIRECT) study, an EU Seventh Framework
Programme (FP7) Innovative Medicines Initiative (see www.
direct-diabetes.org) project.
Study population Diagnosis of diabetes was defined as the
date of the first HbA1c measurement ≥48 mmol/mol (6.5%)
(based on the recommended cut-off point for diagnosing dia-
betes) or the first prescription of glucose-loweringmedication,
following a clinical diagnosis of type 2 diabetes. Individuals
were followed from diagnosis until insulin initiation, death,
leaving the area or end of follow-up (30 September 2015),
whichever came first. To ensure sufficient prescribing infor-
mation and longitudinal HbA1c and BMI measurements, indi-
viduals had to have been diagnosed with diabetes on or after 1
January 1994 to be eligible for the study.
GADA GADA were measured at the time of recruitment into
GoDARTS, allowing us to define a subgroup of individuals
who were ‘GADA positive’ (defined as ≥11 U/l [97.5th
centile]), whom we would expect to have a more rapid pro-
gression of diabetes and show different clinical covariates
associated with progression compared with individuals with
type 2 diabetes [3].
Study criteria The underlying assumption of our progression
model was that change in HbA1c over time was linear, and this
was supported by the Belfast Diet Study, which reported two
linear phases before and after the diagnosis of diabetes [1].
Some individuals who had a high HbA1c at diagnosis and
subsequent marked improvement in HbA1c did not fulfil this
assumption of linearity. Therefore, for all individuals, we re-
stricted the starting HbA1c value to an upper limit of 64 mmol/
mol (8%), and allowed 1 year from diagnosis to reach this
target HbA1c level.
The first HbA1c measure satisfying the inclusion criteria
was defined as the study start for that individual. At least
two subsequent HbA1c measurements were required for an
individual to be included in the analysis. In addition, individ-
uals were required to have a BMI measurement at diagnosis
(defined as the average of all available measures ±1 year from
the diagnosis of diabetes) and at least two subsequent BMI
measures during the follow-up period. A small number of
individuals were also excluded during the analysis as they
had fewer than three HbA1c and/or BMI measures after out-
lying data points had been removed (see below).
Outcome A model was derived for each individual’s
glycaemic deterioration rate based on observed HbA1c mea-
sures from the first eligible HbA1c through to study end.
HbA1c measures were adjusted time-dependently for the fol-
lowing measures:
1. Non-insulin glucose-lowering drugs. Untreated measures
were the reference group, defined as measures prior to
initiation of glucose-lowering drugs. As metformin was
the most commonly prescribed glucose-lowering drug
and we expected to observe a dose-dependent relationship
with HbA1c [14], we divided daily dose into three groups
(<1 g, 1 to <2 g, and ≥2 g). The other glucose-lowering
drugs were grouped solely by drug class, either because
there was no evidence of a dose-dependent relationship
with HbA1c or because the limited number of measures
would result in multiple, small groups. Glucose-lowering
drugs were further grouped into monotherapy, and com-
binations of dual and triple therapy.
2. BMI change. This was expressed as the percentage
change from BMI at diagnosis and categorised into three
groups: stable weight (defined as no more than 5%
change), significant weight gain (increase of ≥5%), and
significant weight loss (decrease of ≥5%).
3. Glucocorticoid use. A widely recognised side effect of
glucocorticoids is to temporarily raise HbA1c [15], and a
significant proportion of individuals were prescribed glu-
cocorticoids during the study period. We categorised use
as ‘yes’ or ‘no’ at each HbA1c measure.
Covariates The following covariates were included in the
model: age at diabetes diagnosis, sex, calendar year of diag-
nosis and a variable indicating high baseline HbA1c at
Diabetologia
diagnosis (i.e. initial HbA1c >64 mmol/mol [8%]). BMI,
HDL-cholesterol and triacylglycerols were also included, de-
fined as the average of all measures ±1 year from diagnosis.
Statistical analysisA linear mixed effects model was fitted. As
the time intervals between HbA1c measurements were more or
less unique to each individual, the ‘continuous time/continuous
space’ spatial data covariance structure provided within the
PROC MIXED procedure in SAS 9.4 (SAS Institute, Cary,
NC, USA) was used to describe the covariance structure
among the errors.
We began by fitting a model with both a fixed and random
intercept and slope, and adjustment for non-insulin glucose-
lowering drugs, glucocorticoid use and changes in BMI over
time, fitted as fixed effects. The Studentised residuals were
examined and any HbA1c measures >3 SD from the mean
were removed as these values were considered likely to be
outliers for that individual.
We then ran the model again for type 2 diabetes and
GADA-positive individuals separately and compared the in-
dividual rates of glycaemic deterioration. These were calcu-
lated by adding together each individual’s random slope with
the population average (fixed) slope.
The model was then expanded in individuals with type 2
diabetes only, owing to small numbers in the GADA-positive
group, to include the baseline clinical covariates of interest. To
model the effect of each covariate on glycaemic deterioration,
an interaction term between the covariate and timewas includ-
ed. We fitted univariate models in which baseline covariates
were added singly, and a multivariate model that included all
univariately significant covariates together. Age at diagnosis
was split into four age bands (<50, 50–<60, 60–<70 and
≥70 years), and BMI was split into five categories based on
WHO definitions (<25, 25–<30, 30–<35, 35–<40 and ≥40 kg/
m2). HDL-cholesterol and triacylglycerol concentrations were
split into four clinically meaningful bands (HDL-cholesterol:
<1, 1–<1.2, 1.2–<1.4 and ≥1.4 mmol/l; triacylglycerols: <1.5,
1.5–<2.5, 2.5–<3.5 and ≥3.5 mmol/l), with an additional
‘missing’ group created to avoid excluding individuals with
missing values from the multivariate model. Calendar year of
diagnosis was divided into quartiles.
All analyses were performed using SAS, and p < 0.05 was
considered statistically significant in all analyses.
Results
Individual characteristics From a total of 6728 individuals
with type 2 diabetes, 5491 (82%) met the study inclusion
criteria. A detailed flow chart of the study population deriva-
tion is presented in ESMFig. 1. Themedian (with interquartile
range [IQR]) study follow-up time was 9.4 (6.1–12.4) years,
and the median (IQR) numbers of HbA1c and BMI measures
per individual were 21 (14–29) and 20 (13–29), respectively.
A total of 121,972 HbA1c measures were generated for the
5491 individuals.
A comparison of characteristics of individuals included in
and excluded from the study is presented in Table 1.
Individuals not meeting the study criteria were younger and
had lower HDL-cholesterol, higher triacylglycerol and higher
HbA1c measurements at diagnosis. In addition, there were
higher proportions of GADA-positive individuals and/or par-
ticipants who had progressed to insulin therapy by the end of
the study period. The characteristics of the three subgroups
within the study population are also presented in Table 1. As
expected, GADA-positive individuals were diagnosed at a
younger age and with a lower BMI, lower triacylglycerols
and higher HDL-cholesterol, and were more likely to progress
to insulin than were individuals with type 2 diabetes.
Linear mixed model-derived effects The linear mixed model
included 76 different drug combinations as fixed effects.
These represent the model-derived estimates for HbA1c reduc-
tion by a particular drug combination compared with no treat-
ment. The drug effects for the most commonly prescribed
combinations (defined as >500 HbA1c measures) are present-
ed in ESM Table 1. There was a total of 33,243 (27.2%)
untreated measures from 3736 (68%) individuals. We ob-
served a dose-dependent relationship with metformin with
<1 g, 1 to <2 g and ≥2 g per day lowering HbA1c on average
(95% CI) by 0.8 (0.4, 1.3) mmol/mol (0.08% [0.03%,
0.12%]), 2.8 (2.5, 3.0) mmol/mol (0.25% [0.23%, 0.28%])
and 4.2 (3.9, 4.6) mmol/mol (0.39% [0.36%, 0.42%]), respec-
tively. A >5% BMI increase was associated with an average
(95% CI) HbA1c increase of 1.2 (1.0, 1.3) mmol/mol (0.11%
[0.09%, 0.12%]). Conversely, a >5% reduction in BMI was
associated with a decrease in HbA1c of on average (95% CI)
2.0 (1.9, 2.2) mmol/mol (0.19% [0.17%, 0.20%]). A total of
4958 (4%) of HbA1c measures were taken while the partici-
pant was on glucocorticoids; these were associated with an
average (95% CI) HbA1c increase of 3.2 (2.8, 3.5) mmol/mol
(0.29% [0.26%, 0.32%]) (BMI and glucocorticoid data not
shown).
Rates of glycaemic deterioration in type 2 diabetic and GADA-
positive individuals The model-derived individual glycaemic
deterioration rate was the rate of change of HbA1c per year
after adjusting for the effect of drug treatment and change in
BMI. The distribution of the individuals’ glycaemic deterio-
ration rate is presented in Fig. 1, with type 2 diabetic (n =
5342) and GADA-positive (n = 149) individuals presented
separately. The mean (95% CI) coefficient of failure for indi-
viduals with type 2 diabetes was 1.4 (1.3, 1.4) mmol/mol
(0.12% [0.12%, 0.13%]) per year, and the median (IQR) was
1.0 (0.4–2.1) mmol/mol (0.09% [0.03–0.10%]). By compari-
son, the coefficient of failure (95% CI) for GADA-positive
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individuals was reached approximately twice as rapidly, at 2.8
(2.4, 3.3) mmol/mol (0.25% [0.20%, 0.31%]) per year with a
median (IQR) 1.9 (0.6–4.8) mmol/mol (0.17% [0.06–0.44%])
(p < 0.0001).
Clinical characteristics associated with glycaemic deteriora-
tion in type 2 diabetesTo investigate which clinical covariates
other than GADA positivity were associated with glycaemic
deterioration, we expanded the model to include baseline clin-
ical covariates within the group with type 2 diabetes. The
results for the overall model are presented in Table 2.
In the univariate analyses, younger age, male sex, HbA1c
>64 mmol/mol (8%) at presentation, earlier calendar year of
diagnosis, higher BMI, lower HDL-cholesterol and higher
triacylglycerols were all associated with a higher rate of
glycaemic deterioration. In the multivariate model, younger
age at diagnosis, lower HDL-cholesterol, higher BMI and ear-
lier calendar year of diagnosis were independently associated
with a higher rate of glycaemic deterioration: individuals di-
agnosed younger than 50 years of age deteriorated on average
(95% CI) 1.67 (1.49, 1.85) mmol/mol (0.15% [0.14%,
0.17%]) HbA1c per year faster than individuals diagnosed
over 70 years of age; individuals with an HDL-cholesterol
<1 mmol/l deteriorated on average (95% CI) 0.21 (0.05,
0.38) mmol/mol (0.02% [0.01%, 0.04%]) per year more
quickly than individuals with an HDL-cholesterol
≥1.4 mmol/l; individuals with a BMI ≥40 kg/m2 deteriorated
on average (95% CI) 0.26 (0.06, 0.47) mmol/mol (0.02%
[0.01%, 0.04%]) per year faster than individuals with a BMI
of 25–30 kg/m2; and individuals diagnosed prior to 2001 de-
teriorated on average (95% CI) 1.55 (1.39, 1.72) mmol/mol
(0.14% [0.13%, 0.16%]) per year faster than individuals diag-
nosed in or after 2006.
To further investigate the relationship between younger age
at diagnosis and higher rate of glycaemic deterioration, the
mean (95% CI) coefficient of failure grouped by 5 year age
bands for individuals with type 2 diabetes is presented in Fig.
2. Of the individuals diagnosed at under 50 years of age, 15%
had a glycaemic deterioration rate of >4.4 mmol/mol (0.4%)
per year, compared with 1.5% of the individuals diagnosed
aged over 70 years. Conversely, 66% of the individuals diag-
nosed over 70 years old had a glycaemic deterioration rate
<1.1 mmol/mol (0.1%) per year compared with just 24% of
the individuals diagnosed under 50 years of age.
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Discussion
In this large, observational, population-based study with a
maximum follow-up period of over 20 years, we have applied
a novel approach to modelling the progression of diabetes. We
have shown that, in a real-world setting, the underlying mean
coefficient of failure (rate of glycaemic deterioration) in indi-
viduals with type 2 diabetes is 1.4 mmol/mol (0.12%) HbA1c
per year, and in GADA-positive individuals it is faster, with a
mean rate of 2.8 mmol/mol (0.25%) per year. Furthermore,
our results suggest that individuals with type 2 diabetes who
deteriorate the fastest are those diagnosed under 50 years old,
Table 2 Differences in estimated
glycaemic deterioration rates in
individuals with type 2 diabetes
Variable n Univariate analysis Multivariate analysis
Unadjusted coefficient
(95% CI)a
p value Adjusted coefficient
(95% CI)b
p value
Age, years
<50 823 1.80 (1.63, 1.97) <0.0001 1.67 (1.49, 1.85) <0.0001
50–<60 1430 0.96 (0.81, 1.11) <0.0001 0.89 (0.74, 1.04) <0.0001
60–<70 1820 0.42 (0.28, 0.57) <0.0001 0.38 (0.24, 0.52) <0.0001
≥70 1269 REF REF
Sex
Male 3013 0.14 (0.03, 0.25) 0.0107 0.06 (−0.04, 0.17) 0.2370
Female 2329 REF REF
Year diagnosed
<2001 1567 1.50 (1.33, 1.67) <0.0001 1.55 (1.39, 1.72) <0.0001
2001–<2003 1318 0.36 (0.26, 0.45) <0.0001 0.38 (0.28, 0.48) <0.0001
2003–<2006 1263 0.10 (0.03, 0.16) 0.0021 0.10 (0.04, 0.17) 0.0010
≥2006 1194 REF REF
Baseline HbA1c >64 mmol/mol:
No 3574 REF REF
Yes 1768 0.19 (0.08, 0.31) 0.0017 0.07 (−0.04, 0.18) 0.2300
BMI (kg/m2):
<25 533 −0.08 (−0.28, 0.11) 0.4008 0.05 (−0.14, 0.23) 0.6387
25–<30 1890 REF REF
30–<35 1703 0.20 (0.07, 0.33) 0.0023 0.07 (−0.05, 0.20) 0.2371
35–<40 774 0.27 (0.10, 0.44) 0.0016 −0.02 (−0.19, 0.14) 0.7887
≥40 442 0.76 (0.55, 0.97) <0.0001 0.26 (0.06, 0.47) 0.0128
HDL-cholesterol (mmol/l):
<1 1275 0.60 (0.44, 0.76) <0.0001 0.21 (0.05, 0.38) 0.0107
1–<1.2 1524 0.41 (0.25, 0.56) <0.0001 0.18 (0.03, 0.34) 0.0188
1.2–<1.4 1168 0.15 (−0.01, 0.32) 0.0673 0.03 (−0.13, 0.19) 0.7291
≥1.4 1119 REF REF
Missing 256 0.01 (−0.25, 0.26) 0.9266 −0.17 (−0.42, 0.09) 0.1850
Triacylglycerol (mmol/l):
<1.5 790 REF REF
1.5–<2.5 1391 0.08 (−0.10 to 0.26) 0.4173 −0.01 (−0.18, 0.17) 0.9315
2.5–<3.5 858 0.16 (−0.03, 0.36) 0.1110 −0.04 (−0.23, 0.15) 0.6677
≥3.5 819 0.36 (0.16, 0.56) 0.0005 −0.03 (−0.22, 0.17) 0.7767
Missing 1484 −0.03 (−0.21, 0. 51) 0.7477 0.07 (−0.11, 0.24) 0.4402
aUnits are mmol/mol HbA1c per year, adjusted only for glucose-lowering medication, steroid use and change in
BMI
bUnits are mmol/mol HbA1c per year, adjusted for glucose-lowering medication, steroid use, change in BMI, age
at diagnosis, sex, year diagnosed, baseline HbA1c group, BMI, triacylglycerols and HDL-cholesterol
Values are expressed as the absolute difference in progression rate between the study group and the reference
group. Positive values mean that the glycaemic deterioration rate is faster than the reference group
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and that there is very limited deterioration in those diagnosed
over the age of 70.
We report a coefficient of failure in individuals with type 2
diabetes comparable to that of the ADOPTclinical trial, which
reported a 1.5 mmol/mol (0.14%) annual rate of deterioration
in HbA1c in a metformin monotherapy cohort [11]. Moreover,
we know from the UKPDS that GADA positivity is a strong
predictor of diabetes progression [3], and here we have shown
that GADA-positive individuals progress approximately two
times faster than individuals with type 2 diabetes. In the group
of individuals who are not known to be GADA-positive, faster
diabetes progression is associated with clinically small but
statistically significant differences in BMI and HDL-choles-
terol, in keeping with the insulin resistance phenotype.
Our findings are in accordance with other studies that have
reported the association between younger age at diagnosis and
faster progression of diabetes [1, 4–8]. Individuals diagnosed
younger than 50 years of age progress rapidly compared with
individuals diagnosed over the age of 70 (Fig. 2), and as
HbA1c at diagnosis is higher in the younger than the older
group (mean [95% CI]: 66.4 [65.1, 67.8] vs 61.9 [60.8,
62.9] mmol/mol; 8.23% [8.11%, 8.35%] vs 7.81% [7.71%,
7.90%]; p < 0.0001), this suggests that individuals diagnosed
younger may benefit from being treated more aggressively
with earlier initiation of glucose-lowering medications, partic-
ularly if future therapies can be established to delay progres-
sion. The finding that, in the real world, 66% of individuals
with type 2 diabetes diagnosed after the age of 70 years prog-
ress at a rate <1.1 mmol/mol (0.1%) per year, and that only
1.5% progress at a rate >4.4 mmol/mol (0.4%) per year, is
striking and highlights how glycaemic monitoring and man-
agement in those diagnosed at over 70 years may not need to
be as aggressive as those diagnosed under 50 years of age.
We have previously reported that earlier calendar year of
diagnosis is associated with risk of progression, as defined by
requirement for insulin treatment [6]. We believe that this
reflects a change in practice over time, with possibly two
factors influencing progression rate. First, individuals may
be diagnosed earlier in more recent years due to screening or
increased awareness. This is supported by the observation that
individuals diagnosed prior to 2001 have a higher HbA1c at
diagnosis than those diagnosed in or after 2006 (mean [95%
CI]: 65.1 [64.1, 66.0] vs 60.5 [59.5, 61.6] mmol/mol; 8.11%
[8.02%, 8.20%] vs 7.68% [7.58%, 7.78%]; p < 0.0001).
Second, with increasing calendar years, there may be im-
proved general health and better treatment of all diabetes risk
factors that may impact on rates of progression.
In this analysis, we included a group who at diagnosis had a
high HbA1c of >64mmol/mol (8%) but whose HbA1c level fell
to meet the inclusion criteria within the first year. Many mech-
anisms may underlie this pattern, but one possible explanation
is that these are a group who initially present with high HbA1c
driven by gluco-lipotoxcity, who subsequently show rapid im-
provement with dietary and drug treatment. It is interesting to
note that, in the multivariate analysis, this group, despite an
initial high HbA1c, subsequently progressed at the same rate
as those whose initial HbA1c was <64 mmol/mol (8%).
The aim of this study was to derive a ‘rate of deterioration’
or ‘coefficient of failure’, which we believe has many advan-
tages over a time to failure model. However, a number of
assumptions have been made in order to develop this model.
First, we assume a linear deterioration in HbA1c; this is sup-
ported by the Belfast Diet Study, which reported two linear
phases before and after the diagnosis of diabetes [1]. However,
there may be individuals who do not follow this linear decline
who are not well accounted for in our model. Second, individ-
uals were excluded from entry into the model largely because
they had a high HbA1c at diagnosis that did not fall below
64 mmol/mol (8%) within the first year, or because they had
too few HbA1c measures before they progressed onto insulin.
As such, our model excludes those with the most aggressive
disease and/or those who present late with a high HbA1c, and
focuses on those diagnosed close to onset of diabetes or with
less aggressive disease. Therefore our coefficients of failure
are likely to underestimate the true progression rate in the
population. Third, we define diabetes diagnosis as a first
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HbA1c ≥48 mmol/mol (6.5%) following a clinical diagnosis
of type 2 diabetes, and as an individual may have a diagnostic
glucose level but an HbA1c <48 mmol/mol (6.5%), this means
that we will underestimate the duration of diabetes and over-
estimate the slope in some individuals. Finally, the fact that we
are studying real-world individuals in clinical practice means
that we lack some key measures that may be important for
glycaemic deterioration, such asmeasures of beta cell function
and insulin resistance.
In summary, we have developed a novel approach to model
the coefficient of failure in observational data across multiple
drug combinations. This approach may be valuable in inves-
tigating biomarker or genomic determinants of diabetes pro-
gression in bioresources. In addition, although our current
model derives a ‘global’ rate of deterioration from diagnosis
to insulin initiation, future developments may allow investi-
gation of how the rate varies for therapies for diabetes and for
other conditions. We confirm that GADAs are associated with
greater glycaemic deterioration, and for the first time quantify
the rate of glycaemic deterioration in the elderly. Our findings
of minimal glycaemic deterioration in this elderly-onset group
has important implications for stratifying diabetes care, sug-
gesting that less intensive glycaemic monitoring and manage-
ment is required for this group.
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